Current aspects of antiandrogen therapy in women

Current Pharmaceutical Design

Volumn 5, Issue 9, 1999, Pages 707-723

  Diamanti Kandarakis, Evanthia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; FINASTERIDE; FLUTAMIDE; SPIRONOLACTONE;

ACNE; ANDROGEN METABOLISM; ARTICLE; DRUG INDUCED DISEASE; HIRSUTISM; HORMONAL THERAPY; HORMONE INHIBITION; HUMAN; HYPERANDROGENISM; MALE TYPE ALOPECIA; PRIORITY JOURNAL;

ANDROGEN ANTAGONISTS; ANDROGENS; CLINICAL TRIALS; FEMALE; HORMONE ANTAGONISTS; HUMANS;

EID: 0345363235     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (119)

1. Redmond, G.P. Androgens and women's health. Int. J. Fertil. Womens. Med., 1998, 43, 91-97.
2. Nahum, R.; Thong, K.J.; Hillier, S.G. Metabolic regulation of androgen production by human thecal cells in vitro. Human Reprod., 1995, 10, 75-81. .
3. El-Roeiy, A.; Chen, X.; Roberts, V.J.; LeRoith, D.; Roberts, Jr. C.T.; Yen, S.S.C. Expression of insulin-like growth factor I (IGF-I) and IGFII and the IGF-I, IGF-II and insulin receptor genes and localization of the gene products in the human ovary. J. Clin. Endocrinol. Metab., 1993, 77, 1411-1418.
4. Erickson, G.F.; Magoffin, D.A.; Dyer, CA.; Hofeditz, C. The ovarian androgen producing cells, A review of structure/function relationships. Endocr. Rev. 1985, 6, 371-399. .
5. Erickson, G.F. Ovarian androgen biosynthesis, endocrine regulation. In , Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women . Philadelphia, Lippincott-Raven, 1997, 3-11.
6. Lobo, R.A. Ovarian hyperandrogenism and androgen-producing tumors. Endocrinol. Metab. Clin. North Am., 1991, 20(4), 773-805.
7. Parker, R.C. Jr. Normal regulation of adrenal androgen production. In, Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women . Philadelphia, Lippincott-Raven, 1997, 23-35.
8. Longcope, C. Androgen Metabolism and Clearance. In, Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women . Philadelphia, Lippincott-Raven, 1997, 37-46.
9. Chen, W.; Zouboulis, C.; Orfanos, C.E. The 5a-reductase system and its inhibitors. Dermatology, 1996, 193, 177-184.
10. Russell, D.W.; Wilson, J.D. Steroid 5α-reductase, Two genes/two enzymes. Annu. Rev. Biochem., 1994, 63, 25-61.
11. Thigpen, A.E.; Silver, R.I.; Guileyardo, J.M.; Casey, M.L.; Mc Connell, J.D.; Russell, D.W. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J. Clin. Invest., 1993, 92, 903-910.
12. Rittmaster, R.S. Androgen conjugates, physiology and clinical significance. Endocr. Rev. 1993, 13, 1-14.
13. st Annual Meeting of the Endocrine Society, San Diego, Calofornia, 1999, Abstract P1-451.
14. Longcope, C. Androgen metabolism. In, Sciarra JJ, Speroff L, Simpson JL, eds. Gynecology and Obstetrics. vol.5, Philadelphia, J.B. Lippincott, 1994, 1-13.
15. Maroulis, G.B.; Abraham, G.E. Diagnostic tests in hirsutism. In, Mahesh Vb, Greenblatt RB, eds. Hirsutism and virilism, Pathogenesis, diagnosis and management. Boston, John Wright PSG, 1983, 295-307.
16. Diamanti-Kandarakis, E.; Dunaif, A. New perspectives in polycystic ovary syndrome. Trends Endocrinol. Metab., 1996, 7, 267-271 .
17. Diamanti-Kandarakis, E. The polycystic ovary syndrome, pathogenesis, metabolic implications and therapeutic approach. Annals of the New York Academy of Sciences. Adolescent Gynecology and Endocrinology Basic and Clinical Aspects, 1997, 816, 177-193 .
18. Wild, R.A.; Grubb, B.; Hartz, A. et al. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 1990, 54, 255-259.
19. Rosenfield, R.L.; Deplewski, D. Role of androgens in the developmental biology of the pilosebaceous unit. Am. J. Med., 1995, 98(Suppl. 1A), 80S-88S.
20. Kealey, T.; Philpott, M.; Guy, R. The regulatory biology of the human pilosebaceous unit. Bailliere Æs Clinical Obstretics and Gynaecology, 1997, 11(2), 205-227.
21. Conn, J.J.; Jacobs, H.S. Managing hirsutism in gynaecological practice. Br. J. Ostet. Gynaecol., 1998, 105, 687-696.
22. Randall, V.A. Androgens and human hair growth. Clin. Endocrinol., 1994, 40, 439-457.
23. Thiboutot, D.M. Normal Physiology of the Pilosebaceous Unit. In, Azziz R, Nestler JE, Dewailly, D eds. Androgen Excess Disorders in Women. Philadelphia, Lippincott-Raven, 1997, 103-114.
24. st Annual Meeting of the Endocrine Society, 1999, San Diego, California, Abstract P1-459.
25. Kutten, F.; Mowszowicz, I.; Schaison, G.; Mauvais-Jarvis, P. Androgen production and skin metabolism in hirsutism . J. Endocrinol., 1977, 75, 83-89.
26. Futterweit, W. Polycystic Ovary Syndrome, Clinical Perspectives and Management. Obstetrical and Gynecological Survey, 1999, 54, 403-413.
27. Barnes, R.B. Diagnosis and therapy of hyperandrogenism. BailliereÆs Clinical Obstetrics and Gynecology , 1197, 11(2), 369-396.
28. Ferrimann, D.; Gallway, J.D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab., 1996, 21, 1440-1447.
29. st Annual Meeting of the Endocrine Society, 1999, San Diego, California, Abstract P3-337.
30. Guzic, D. Polycystic ovary syndrome, Symptomatology, pathophysiology, and epidemiology. Am. J. Obstet. Gynecol., 1998, 179, S89-93.
31. Futterweit, W. Clinical Evaluation of Androgen Excess. In, Azziz R, Nestler JE, Dewailly D, eds. Androgen Excess Disorders in Women . Philadelphia, Lippincott-Raven, 1997, 625-633.
32. Reingold, S.B.; Rosenfield, R.L. The relationship of mild hirsutism or acne in women to androgens. Arch. Dermatol., 1987, 132, 209-212.
33. Lucky, A.W.; McGuire, J.; Rosenfield, R.L.; Lucky, P.A.; Rich, B.H. Plasma androgens in women with acne vulgaris. J. Invest. Dermatol., 1983, 81, 70-74.
34. Lawrence, D.; Shaw, M.; Katz, M. Elevated free testosterone concentrations in men and women with acne vulgaris. Clin. Exp. Dermatol., 1986, 11, 263-279.
35. Van Neste, D.J.J.; Rushton, H. Hair problems in women. Clinics in Dermatology, 1997, 15, 113-125.
36. Futterweit, W.; Dunaif, A.; Yeh, H.C.; Kingsley, P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J. Am. Acad. Dermatol., 1988, 19, 831-836.
37. Robyn, C.; Tukumbane, M. Hyperprolactinemia and hirsutism. In, Mahesh VB, Greemblatt RB, eds. Hirsutism and virilism, pathogenesis, diagnosis and management. Boston, J. Wrihgt PSG Inc, 1983, 189-211.
38. Berga, S.L. The obstetrician-gynecologist's role in the practical management of polycystic ovary syndrome. Am. J. Obstet. Gynecol., 1998, 179, S109-113.
39. Ehrmann, D.A.; Rosenfield RL. An endocrinologie approach to the patient with hirsutism. J. Clin. Endocrinol. Metab., 1990, 71, 1-4.
40. Taylor, A.E. Understanding the underlying metabolic abnormalities of polycystic ovary syndrome and their implications. Am. J. Obstet. Gynecol., 1998, S94-100.
41. Diamanti-Kandarakis, E.; Mitrakou, A.; Hennes, M.M.I.; Platanissiotis, D.; Kaklas, N.; Spina, J.; Georgiadou, E.; Hoffmann, R.G.: Kissebah, A.H.; Raptis, S. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovarian syndrome. Metabolism 1995, 44, 525-531.
42. Diamanti-Kandarakis, E.; Kouli, C.; Bergiele, A.; Filandra, F.; Tsianateli, T.; Spina, G.; Zapanti, E.; Bartzis, M. A survey of the polycystic ovary syndrome in the greek island of Lesbos, hormonal and metabolic profile. J. Clin. Endocrinol. Metab., 1999 (in Press).
43. Barbieri, R.I. Hyperandrogenism, insulin resistance and acanthosis nigricants, 10 years of progress.J. Reprod. Med., 1994, 39, 327-336.
44. Diamanti-Kandarakis, E.; Tolis, G.; Duleba, A. Androgens and therapeutic aspects of antiandrogens in women. J. Soc. Gynecol. Invest., 1995, 2, 577-592.
45. Eil, C.; Edelson, S.K. The use of human skin libroblasts to obtain potency estimates of drug binding to androgen receptors. J. Clin. Endocrinol. Metab., 1984, 39, 51-55.
46. Menard, R.H.; Guenthner, T.M.; Kon, H.; Gilette, J.R. Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. J. mol. Chem., 1979, 254, 1726-1733.
47. Serafini, P.C.; Catelino, J.; Lobo, R.A. The effect of spironolactone on genital skin 5α-reductase activity. Steroid Biochem., 1985, 15, 363-371.
48. Diamanti-Kandariakis, E. How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome? J.Endocrinol.Invest. 1998, 21, 623-629.
49. Gardiner, P.; Schrode, K.; Quinlan, D.; Martin, B.K.; Boreham, D.R.; Stubbs K, Smith M, Karim A. Spironolactone metabolism, Steady-state serum levels of the sulfur-containing metabolites. J. Clin. Pharmacol., 1989, 29, 342-347.
50. Tremblay, R.R. Treatment of hirsutism with spironolactone. J. Clin. Endocrinol. Metab., 1986, 15, 363-371.
51. Erenus, M.; Yucelten, D.; Durmusoglu, F.; Gurbuz, O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil. Steril., 1997, 68, 1000-1003.
52. Kelestimur, F.; Sahin, Y. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil. Steril., 1998, 69, 66-69.
53. Cumming DC, Yang JC, Rebar RW, Yen SSC. Treatment of hirsutism with spironolactone. JAMA, 1982, 247, 1295-1298.
54. Sciarra, F.; Toscano, V.; Concolino, G.; Di Silverio, F. Androgens, clinical applications. J Steroid Biochem. Mol. Biol., 1990, 37, 349-362. .
55. Sahin, Y.; Bayram, F.; Kelestimur, F.; Muderris, I. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. J. Endocrinol. Invest., 1998, 21, 348-352.
56. Vermeulen, A.; Rubens, R. Effects of cyproterone acetate plus ethinyl estradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women. Contraception, 1988, 38, 419-428.
57. Stivel, M.S.; Kauli, R.; Kaufman, H.; Laron, Z. Adrenocortical function in children with precocious sexual development during treatment with cyproterone acetate. Clin. Endocrinol., 1982, 16, 163-169.
58. De-Leo, V.; La Marca, A.; Lanzetta, D.; Cariello, P.L.; D'Antona, D.; Morgante, G. Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF). Clin. Endocrinol., 1998, 49(1), 85-89.
59. De Leo, V.; Lanzetta, D.; DÆ Antona, D.; La Marca, A.; Morgante, G. Hormone effects of flutamide in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 1998, 83, 99-102.
60. Schultz, M.; Schmoldt, A.; Donn, F.; Becker, H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J. Clin. Pharmacol., 1988, 34, 633-636.
61. Fruzzetti, F.; Bersi, C.; Parrini, D.; Ricci, C.; Genazzani, A.R. Treatment of hirsutism, comparisons between different antiandrogens with central and peripheral effects. Fertil. Steril., 1999, 71 (3), 445-451.
62. Marcondes, J.A.M.; Minnani, S.L.; Luthold, W.W.; Wajchenberg, B.L.; Samojlik, E.; Kirshner, M.A. Treatment of hirsutism in women with flutamide. Fertil. Steril., 1992, 57, 543-547. .
63. Balzano, S.; Cappa, M.; Migliari, R.; Scarpa, R.M.; Danielli, E.; Campu, s G.; Pintus, C.; Sica, V.; Usai, E.; Martino, E. The effect of flutamide and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. J. Endocrinol. Invest., 1988, 11, 693-696.
64. Diamanti, E.; Kaklas, N.; Georgiadou, E.; Spina, J.; Rangou, D.; Chlouverakis, C. The impact of a pure antiandrogen on gonadotropin and prolactin secretion in women with PCOS. Second International Capri Conference 1992, Abstract 106.
65. Wysowski, D.K.; Freiman, J.P.; Tourtelot, J.B.; Horton, M.L. Fatal and non-fatal hepatotoxicity associated with flutamide. Ann. Intern. Med., 1993, 118, 860-864.
66. Wallace, C, Lalor, E.A.; Chik, C.L. Hepatotoxicity complicating flutamide treatment of hirsutism. Ann. Intern. Med., 1993, 119, 1150. .
67. Rosman, A.S.; Frissora-Rodeo, C.; Marshal, A.T.; Reiter, B.P. Cholestatic hepatitis following flutamide. Dig. Dis. Sci., 1993, 38, 1756-1759.
68. Rittmaster, R.S.; Finasteride,. N. Engl. J. Med., 1994, 330, 120-125.
69. Li, X.; Chen, C.; Singh, S.M.; Labrie, F. The enzyme and inhibitors of 4-ene-3-oxosteroid 5α-oxidoreductase. Steroids, 1995, 60, 430-441.
70. Tolino, A.; Petrone, A.; Sarnacchiaro, F.; Cirillo, D.; Ronsini, S.; Lombardi, G.; Nappi, C. Finasteride in the treatment of hirsutism, new therapeutic perspectives. Fertil. Steril., 1996, 66, 61-65.
71. Castello, R.; Tosi, F.; Perrone, F.; Negri, C.; Muggeo, M.; Moghetti, P. Outcome of long-term treatment with 5α-reductase inhibitor finasteride in idiopathic hirsutism, clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil. Steril., 1996, 66, 734-740.
72. Moghetti, P.; Castello, R.; Negri, C.; Tosi, F.; Magnani, C.M.; Fontanerosa, M.C.; Armanini, D.; Muggeo, M. Flutamide in the treatment of hirsutism, long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil. Steril., 1995, 64(3), 511-517.
73. Bayram, F.; Muderris, I.I.; Sahin, Y.; Kelestimur, F. Finasteride treatment for one year in 35 hirsute patients. Exp Clin. Endocrinol. Diabetes.; 1999, 107, 195-197.
74. Pazos, F.; Escobar-Morreale, H.F.; Balsa, J.; Sancho, J.M.; Varela, C. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil. Steril., 1999, 71, 122-128.
75. Erenus, M.; Yucelten, D.; Gurbuz, O.; Durmusoglu, F.; Pekin, S. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil. Steril., 1996, 66(2), 216-219.
76. Venturoli, S.; Matrscalchi, O.; Colombo, F.M.; Macrelli, S.; Ravaiolo, B.; Bagnoli, A.; Paradisi, R.; Flamigni, C. A prospective randomized trial comparing low dose flutanide, finasteride, ketoconazole and cyproterone acetate - estrogen regimens in the treatment of hirsutism. J. Clin. Endocrinol. Metab., 1999, 84, 1304-1310.
77. Cusan, L.; Dupont, A.; Belanger, A.; Tremblay, R.R.; Manhes, G.; Labrie, F. Treatment of hirsutism with the pure antiandrogen flutamide. J. Am. Acad. Dermatol., 1990, 23, 462-469.
78. Ciotta, L.; Cianci, A.; Marletta, E.; Pisana, L.; Agliano, A.; Palumbo, G. Treatment of hirsutism with flutamide and a low dosage oral contraceptive in polycystic ovarian disease patients. Fertil. Steril., 1994, 62, 1129-1135.
79. Couzinet, B.; Pholsena, M.; Young, J.; Schaison, G. The impact of a pure antiandrogen (flutamide) on LH, FSH androgens and clinical status in idiopathic hirsutism. Clin. Endocrinol., 1993, 39, 157-162. .
80. Shaw, J.C. Antiandrogen and hormonal treatment of acne. Dermatologic Clinics, 1996, 14(4), 803-811.
81. Muderris, I.I.; Bayram, F.; Sahin, Y.; Kelestimur, F.; Tutus, A.; Ayata, D. The efficacy of 250mg of flutamide in the treatment of patients with hirsutism. Fertil. Steril., 1996, 66, 220-222.
82. Muderris, I.I.; Bayram, F. Clinical efficacy of lower dose flutamide 125mg/day in the treatment of hirsutism. J. Endocrinol. Invest., 1999, 22, 165-168.
83. Diamanti-Kandarakis, E.; Mitrakou, A.; Raptis, S.; Tolis, G.; Duleba, A. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 1998, 83, 2699-2705.
84. Lobo, R.A.; Shoupe, D.; Serafini, P. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil. Steril., 1985, 43, 200-205.
85. Shapino, G.; Evron, S. A novel use of spironolactone, Treatment of hirsutism. J. Clin. Endocrinol. Metab., 1980, 51, 429-435.
86. Barth, J.H.; Cherry, C.A.; Wojnarowska, F.; Dawber, R.P.R. Spironolactone is an effective and well tolerated systemic antiandrogen tharepy for hirsute women. J. Clin. Endocrinol. Metab., 1989, 68, 966-970.
87. Wong, I.L.; Morris, R.S.; Chang, L.; Spahn, M.: Stanczyk, F.Z.; Lobo, R. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metab., 1995, 80, 233-238. .
88. Erenus, M.; Yucelten, D.; Gurbuz , O.; Durmusoglu, F.; Pekin, S. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil. Steril., 1996, 66, 216-219.
89. Fruzzetti, F.; De Lorenzo, D.; Parrini, D.; Ricci, C. Effects of finasteride, a 5α-reductase inhibitor, on circulationg androgens and gonadotropin secretion in hirsute women. J. Clin. Endocrinol. Metab., 1994, 79, 831-835.
90. Moghetti, P.; Castello, R.; Magnani, C.; Tosi, F.; Negri, C.; Armanini, D.; Bellotti, G.; Muggeo, M. Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism. J. Clin. Endocrinol. Metab., 1994, 79, 1115-1121.
91. Faloia, E.; Filipponi, S.; Mancini, V.; Di Marco, S.; Mantero, F. Effect of finasteride in idiopathic hirsutism. J. Endocrinol. Invest., 1998, 21, 694-698.
92. Ciotta, L.; Cianci, A.; Calogero, A.E. Clinical and endocrine effects of finasteride, a 5α-reductase inhibitor, in women with idiopathic hirsutism. Fertil. Steril., 1995, 64, 299-306.
93. Erenus, M.; Gurbuz, O.; Durmusoglu, F.; Demircay, Z.; Pekin, S. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil. Steril., 1994, 61, 613-616.
94. Falsetti, L.; De Fusco, D.; Eleftheriou, G.; Rosina, B. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. Gynecol. Endocrinol., 1997, 11, 251-257.
95. Gregoriou, O.; Papadias, C.; Konidaris, S.; Antoniou, G.: Karakitsos, P.; Giannikos, L. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism, a randomized controlled trial. Gynecol. Endocrinol., 1996, 10, 119-123.
96. Beylot, C.; Doutre, M.S.; Beylot-Barry, M. Oral contraceptives and cyproterone acettate in female acne treatment. Dermatology, 1998, 196, 148-152.
97. Van Wayjen, R.G.; van den Ende, A. Experience in the long term treatment of hirsutism and/or acne with cyproterone acetate-containing preparations, Efficacy, metabolic and endocrine effects. Exp. Clin. Endocrinol. Diabetes, 1995, 103, 241-251.
98. Charoenvisal, C.; Thaipisuttikul, Y.; Pinjaroen, S.; Krisanapan, O.; Benjawang, W.; Koster, A.; Doesburg, W. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int. J. Fertil. Menopausal. Stud., 1996, 41, 423-429.
99. Burke, B.M, Cunliffe, W.J. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br. J. Dermatol., 1985, 112, 124-125.
100. Asscher, A.W. Spironolactone. Curr. Probl., 1988, 21, 3-4 . .
101. Muhlemann, M.F.; Carter, G.D.; Cream, J.J. Oral spironolactone, An effective treatment for acne vulgaris in women. Br. J. Dermatol., 1986, 115, 227-232. .
102. Shaw, J.C. Spironolactone in dermatologic therapy. J. Am. Acad. Dermatol., 1991, 24, 236-243.
103. Gruber, D.M.; Sator, M.O.; Joura, E.A.; Kokoschka, E.M.; Heinze, G.; Huber, J.C. Topical cyproterone acetate treatment in women with acne. Arch. Dermatol., 1998, 134, 459-463.
104. Nielsen, P.G. Treatment of female acne vulgaris with a cream containing the antiandrogen canrenone. Dermatologica, 1983, 166, 275-276 .
105. Lookingbill, D.P.; Abrams, B.B.; Ellis, C.N. The effect of a topical antiandrogen inocoterone acetate (RU 882) on acne , results of a multicenter clinical trial. Arch. Dermatol., 1992, 128, 1197-1200.
106. Rushton, D.H.; Ramsay, I.D. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl estradiol treatment of diffuse androgen dependent alopecia in women. Clin. Endocrinol., 1992, 36, 421-427. .
107. Ramsay, I.D.; Rushton, D.H. Reduced serum vitamin B12 levels during oral cyproterone acetete and ethinyl estradiol therapy in women with diffuse androgen dependent alopecia. Clin. Exp. Dermatol., 1990, 15, 277-281.
108. Rushton, D.H.; Futterweit, W.F.; Kingsley, D.H.; Kingsley, P.; Norris, M.J. Quantitative assessment of spironolactone treatment in women with diffuse androgen dependent alopecia. J. Soc. Cosmet. Chem.; 1991, 42, 317-325.
109. Waldstreicher, J. The effect of finasteride on postmenopausal women with androgenetic alopecia. Program of the 81st Annual Meeting of the Endocrine Society, San Diego, California, 1999 Abstract P1-462.
110. Smith, K.D.; Rodriguez-Rigau, L.J.; Tcholakian, R.K.; Steinberger E. The relation between plasma testosterone levels and the lengths of phases of the menstrual cycle. Fertil. Steril., 1979, 32, 403-407.
111. Rodriguez-Rigau, L.J.; Petak, S.M.; Leite, Z.; Smith, K.D.; Steinberger, E. Therapy of hyperandrogenism. In, Frajese G, Steinberger E, Rodriguez-Rigau LJ, eds. Reproductive medicine, Medical therapy.Amsterdam, Excerpta Medica, 1989, 69-77.
112. Dunaif, A.; Green, G.; Futterweit, W.; Dobrjansky, A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 1990, 70, 699-704.
113. Dunaif, A. Insulin resistance and the Polycystic Ovary Syndrome, Mechanism and Implications for Pathogenesis. Endocr. Rev. 1997, 18(6), 774-800.
114. Elkind-Hirsch, K.E.; Valdes, C.T.; Malinak, L.R. Insulin resistance improves in hyperandrogenic women treated with Lupron. Fertil. Steril., 1993, 60, 634-641.
115. Moghetti, P.; Tosi, F.; Castello, R.; Magnani, C.M.; Negri, C.; Brun, E.; Furlani, L.; Caputo, M.; Muggeo, M. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment, evidence that androgens impair insulin action in women. J. Clin. Endocrinol. Metab., 1996, 81, 952-960.
116. Baischer, W.; Koining, G.; Hartmann, B.; Huber , J.; Langer, G. Hypothalamic-pituitary-gonadal axis in depressed women-elevated blood testosterone concentrations compared to normal controls. Psychoneuroendocrinology, 1995, 20, 553-559.
117. Bergman, L.; Eriksson, E. Marked symptom reduction in two women with bulimia nervosa treated with the testosterone receptor antagonist flutamide. Acta. Psychiatr. Scand., 1996, 94, 137-139.
118. Peterson , B.S.; Zhang, H.; Anderson, G.M.; Leckman, J.F. A double-blind placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette's syndrome. J. Clin. Psychopharmacol., 1998, 18, 324-331.
119. Moran, C.; Alcivia, J.C.; Garcia-Hernandez, E.; Castro, J. Treatment of endometriosis with cyprotreone acetate. Preliminary report. Arch. Med. Res., 1996, 27(4), 535-538.